Positive Phase 1 data for CTX310® presented in a late-breaking presentation at the American Heart Association (AHA) ...

An experimental gene-editing therapy developed by Crispr Therapeutics is showing promise for treating heart disease.

Explore CRISPR technology explained, gene editing science, DNA modification, and genetic engineering ethics—discover how ...

Clustered regularly interspaced palindromic repeats(CRISPR) gene editing, known for its precision, is revolutionizing tumor research and treatment. This article covers the evolution of the CRISPR ...

Data presented in a late-breaking presentation at the American Heart Association (AHA) Scientific Sessions 2025--Phase 1 ...

Over the past two decades, synthetic biology has fueled advancements across a broad range of disciplines, including agriculture, bioremediation, biofuel production, and chemical manufacturing. Today, ...

In a 15-patient, Phase 1, first-in-human trial, a one-time CRISPR-Cas9 gene-editing therapy safely reduced LDL cholesterol ...

UniQure stock dropped after the FDA sent feedback on the company's pending treatment for Huntington's disease. Read more on ...

Traditional breeding and genetic modification methods have struggled to keep pace with the rapid evolution of plant viruses. CRISPR/Cas systems, originally derived from bacterial immune responses, ...

On a more microscale (literally), microlearning has been shown to help “protect mental health and support resilience” by ...

Explore how oligonucleotides are reshaping therapeutics, diagnostics and CRISPR with rapid, scalable and personalized ...

Detailed price information for Crispr Therapeutics Ag (CRSP-Q) from The Globe and Mail including charting and trades.